Synergistic senolytic-regenerative therapy significantly extends healthspan and lifespan.

Thomas E Ichim, Nikola Markov, Gilberto Lopes, Karenjan A Pascual, Anastasiia Evans, Robert Reznik, Vladyslav Bykoriz, Christian A Fortunati, Boris Minev, Roman A Ramos, Anil Bajnath, Emma Lin, Joyce Hu, Francesco M Marincola, Armin Rath, Barbie Barrett, Andrew Jurow, Kamlesh Kumar Sankhala, David Furman, Boris N Reznik

Immorta Bio Inc., Miami, FL, US. [email protected] Bio Inc., Miami, FL, US. [email protected]. · pubmed

Paper

Abstract

Current barriers to achieving radical life extension include the inability to use syngeneic, youthful mesenchymal stem cells (MSCs) and the anti-regenerative effects of senescence-associated secretory phenotype (SASP) factors. We aim to overcome this by a combination approach in which senescent cell burden is reduced utilizing SenoVax™ a dendritic cell based senolytic immunotherapy combined with syngeneic pluripotent stem cell derived MSC.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that a combination of senolytic immunotherapy and syngeneic MSCs can significantly extend healthspan and lifespan. This research addresses the root causes of aging by targeting senescent cells and enhancing regenerative capacity, which is central to longevity studies.

Author of this paper? Send a correction.